Objective-Analysis of the distribution of endothelial cell tissue plasminogen activator (tPA) in the vasculature of rodents and primates demonstrated that tPA is constitutively expressed predominately in small artery endothelial cells of brain and lung. The regulatory elements responsible for the highly selective expression of arterial endothelial cell tissue plasminogen activator were sought. Methods and Results-Transcription factor binding sites were defined by electrophoretic mobility-shift assay (EMSA) analysis using rat lung and brain nuclear extracts and the tPA promoter sequence from Ϫ609 to ϩ37 bp. Protein binding to the promoter was found to be mediated by an NF1 site between Ϫ158 and Ϫ145 bp upstream from the transcriptional start site. Specific binding was confirmed through mutational analysis and competition binding studies. Infection of endothelial cells with a tPA promoter-green fluorescent protein (GFP) (Ϫ609 to ϩ37 bp) reporter construct resulted in expression of the GFP, whereas no expression was found in smooth muscle cells. Mutation of the NF1 site increased the GFP expression indicating that the element acts as a repressor. Conclusions-These results suggest that the 600 bp of the tPA promoter upstream of the transcription start site conveys cell specificity to tPA expression and that an NF1 site within this region acts as a repressor. 
T he endothelium is a functionally heterogeneous group of cells that respond to the diverse needs of specific tissue and organ environments, both constitutively and in response to changing physiological and pathologic conditions. 1, 2 Little is known about the origins of phenotypic diversity of endothelial cells, although inheritance from distinct sublineages (clonality) and microenvironmental effects have been proposed. 3, 4 The role of environmental factors promoting specific endothelial phenotypes involves the interaction of endothelial cells with other cell types such as astrocytes, smooth muscle cells, and myocytes, as well as the hemodynamic forces within the vessel lumen. These factors promote gene transcription of specific endothelial cell genes leading to unique endothelial cell phenotypes. [5] [6] [7] [8] One protein whose expression is highly regulated in endothelial cells is tissue plasminogen activator (tPA). tPA expression occurs in a selective subset of endothelial cells that are defined by both vessel type and organ. 9 -11 The production of tPA and its secretion into the vasculature has been long assumed to be the responsibility of all endothelial cells. However, studies have demonstrated that in vivo expression of tPA is restricted to a distinct minority of endothelial cells. Immunohistochemical and in situ hybridization analysis of several large vessels in the nonhuman primate showed tPA antigen and mRNA exclusively localized to the endothelium of the vasa vasora, with none found in the large vessel endothelium. 11 Physiological studies have indicated that tPA also is found in the brachial and coronary arteries. [12] [13] [14] When a more thorough analysis of tPA distribution was performed in rodents, endothelial cell tPA expression was found to be predominately localized to the pulmonary arterial endothelium and the pia mater of the brain. 14, 15 This suggests that constitutive tPA expression is a characteristic of specific endothelial cells.
There have been numerous studies on the molecular regulation of tPA. 15,16 -18 Some of the experiments involved promoter mapping studies using various types of cultured cells, whereas others have used transgenic animals in which various lengths of promoter were inserted and site specific reporter-gene expression documented. Studies on endothelial cell regulation have been performed primarily with cultured cells from sources that do not express the protein in vivo. Because endothelial cells from most sources begin to express tPA when placed in culture it is not clear whether the results from the studies performed in vitro represent the mechanisms used in the intact animal. In the present study, we have characterized the tPA 5Ј flanking region for elements that promote constitutive tPA expression within the endothelial cells of the brain and lung arterioles using freshly prepared tissues. We have examined the first 600 bp upstream from the transcriptional start site, a sequence that contains a region of homology between the rat, mouse, and human promoter, for protein binding activity and have identified the participation of an NF-1 consensus sequence.
Methods

Nuclear Extract Preparation and EMSA
Nuclear extracts were prepared from the brains and lungs of 15-day-old rats (Harlan Breeders, Indianapolis, IN). Animals were anesthetized, decapitated, and the brains, lungs, kidneys, and livers removed and placed in buffer A (10 mmol/L HEPES, pH 7.9, 25 mmol/L KCl, 1 mM EGTA, 1 mmol/L EDTA, 0.32 mol/L sucrose, 0.15 mmol/L Spermine, 0.5 mmol/L spermidine, 1 mmol/L DTT, 0.5 mmol/L PMSF, 0.1 mmol/L Benzamidine, 1X complete protease inhibitor cocktail [Roche Molecular Biochemicals]), finely minced, and the volume of buffer A increased to a final volume equaling 5ϫ the tissue weight. The samples were homogenized and the homogenate diluted 2 times in buffer A containing 2 mol/L sucrose. This mixture was layered onto undiluted buffer A containing 2 mol/L sucrose and the nuclei isolated by centrifugation for 45 minutes at 70 000g at 4°C. The nuclear pellet was washed twice in 600 L of buffer A containing 20% glycerol and homogenized. To extract the nuclear proteins, 400 L of buffer A containing 20% glycerol and 1 mol/L KCl was added to the nuclear homogenate and the mixture incubated for 1 hour at 4°C with rocking. The samples were centrifuged at 244 587g for 50 minutes at 4°C. Nuclear extracts were partially purified by ion exchange chromatography using DEAE-Sephacel. Fractions containing eluted protein were dialyzed against 10 mmol/L Tris-HCl, pH 7. To identify potential binding sites within the promoter Ϫ609 to ϩ37, oligonucleotide probes representing 4 overlapping regions of Ϸ300 base pairs each were generated by polymerase chain reaction (PCR)-labeled on the 5Ј end with biotin. The oligonucleotides were added at final concentration of 20 fmol to the reactions mixture containing 10 mmol/L Tris, pH 7.5, 50 mmol/L KCl, 1 mmol/L dithiothreitol, 50% glycerol, 100 mmol/L MgCl 2, 1 g/L Poly(dI⅐dC), and 1% NP-40, and, if required, 2 pmol of specific or nonspecific competitor. The mixture was incubated for 90 minutes at room temperature and fractionated on 6% polyacrylamide gels. The contents of the gel were transferred to nitrocellulose and detection of the biotin labeled DNA was performed using the LightShift Chemiluminescent electrophoretic mobility-shift assay (EMSA) kit (Pierce). Oligonucleotides that bound protein were fragmented into 100-bp pieces using PCR and EMSA analysis repeated. Further reduction in fragment size was achieved by synthesis of the promoter fragment sequence of interest as complimentary single strands and annealing by equimolar mixing. Mutational analysis of the NF1 site was performed by synthesizing oligonucleotides corresponding to the 5Ј and 3Ј regions of the promoter fragment, which contained the required base substitutions. The NF1 mutation in the 663-bp promoter inserted into the adenoviral vector was generated by cloning the tPA promoter fragment into pGEM4Z and the mutated DNA generated by PCR using complimentary primers designed to introduce the mutation GCC to TAA (5Ј-AGCTGGCGTCAATAAAAG-AGTGGCT-3Ј). After PCR, DpnI was added for 1 hour at 37°C to digest the methylated template plasmid. The remaining plasmid was transformed into competent DH5␣ Escherichia coli and isolated plasmids sequenced to insure the appropriate substitution had occurred.
Promoter Constructs and Adenovirus Preparation and Production
To generate the tPA promoter-green fluorescent protein (GFP) gene construct, the cytomegalovirus (CMV) promoter was removed from the pQBI25 Vector with Sac II and Bgl II and the linearized, promoter-less pQBI25 was gel-purified and blunt-ended by 5Ј-fill-in reaction. The tPA promoter fragment spanning region Ϫ623 to ϩ43 was blunt-end ligated to the promoter-less pQBI25 and the proper orientation confirmed by restriction digests. The tPA Promoter ϪGFP-BGHpolyA fragment was excised by Ssp I and Dra III digestion, blunt-ended, and ligated into pGEM4Z. The insert was removed with Hind III and Kpn I and cloned into the pShuttle Vector (Dr Bert Vogelstein, John Hopkins University, Baltimore, Md). The Pme I linearized plasmid was purified and coelectroporated with pAdeasy adenoviral backbone vector into BJ5183 electrocompetent cells. Large amount of plasmid DNA was obtained by double CsCl purification technique.
HEK293 cells were cotransfected with 8 pg of pJM17 and 2 pg of the plasmid DNA by calcium phosphate coprecipitation. After overnight incubation, cells were overlaid with minimum essential medium containing 1% fetal bovine serum (FBS) and 0.75% Bactoagar. Overlay was repeated on days 3 and 6. On day 9, minimum essential medium/FBS/Bacto-agar containing 0.01% neutral red was added to visualize the plaques, which were picked up on day 10. Integrity of the constructs was verified by Southern blot analysis. HEK 293 cells were infected at a multiplicity of infection of 5. Forty-eight hours later, cells were harvested and suspended in hypotonic buffer (10 mmol/L Tris-C1, pH 8.0, 1 mmol/L MgCl,) and the cells disrupted by freezing and thawing. The supernatant was further purified by ultracentrifugation in cesium chloride gradient and dialyzed against isotonic saline (135 mmol/L NaC1, 5 mmol/L KCl, 1 mmol/L MgCl, 10 mmol/L Tris-C1, pH 7.4). The concentration of adenovirus particles was determined by optical density at 260 nm and by the plaque forming assay (100 particlesϭ1 plaqueforming unit [pfu]).
Assessment of GFP Expression in Cultured Cells
HeLa cells and smooth muscle cells were cultured in DMEM with 10% fetal calf serum and dermal endothelial cell and umbilical vein endothelial cells were grown in EGM-2 medium (Clonetics) until confluence was achieved. Before infection, the adenovirus was diluted to 5.0ϫ10 6 pfu/mL in the appropriate growth medium and the cells infected with either 20 pfu/cell (fluorescent microscopy) or 50 pfu/cell (fluorescence-activated cell sorter [FACS] ). The cells were incubated for 24 hours to 48 hours at 37°C. For fluorescence microscopy, cells were washed with PBS and images captured with a Leica fluorescence microscope equipped with a Hamamatsu CCD camera and images analyzed using the Openlab Software (Improvision). For FACS analysis, the cells were washed with phosphatebuffered saline twice and removed from the dish with trypsin. The cells were resuspended in 300 L of cold 2% FBS and FACS analysis was performed with a Becton-Dickinson FACScan calibrated before use with CaliBRITE Beads (Becton-Dickinson). Data were acquired using CellQuest Software.
Results
Protein Binding Activity
Comparison of the rat, 19, 20 mouse, 15, 21 and human 22 tPA promoter sequence shows a high degree of homology within the first 300 bp proximal to the transcriptional start sites (Figure 1 ). The protein binding activity of a 600 bp fragment (Ϫ609 to ϩ37) of the rat tPA promoter was examined by EMSA analysis using nuclear extracts derived from rat brain or lung. In the brain, both endothelial cells and neurons express tPA, 10, 11, 23 whereas in the lung, endothelial cells are the only source of this protein. 10, 11 Therefore, to maximize the likelihood that endothelial cell-specific elements were being identified, only results that were identical with both lung and brain extracts were pursued. The initial EMSA analysis was performed with oligonucleotides representing 4 overlapping promoter fragments of Ϸ300 bp each. Specific binding was observed with fragment 1 (Ϫ287 to ϩ37) and fragment 2 (Ϫ342 to Ϫ53). Two bands appeared in each and lung and brain had identical patterns with each probe ( Figure 2B ). To determine the sequence to which the proteins bound, fragment 1 was divided further into increasingly smaller overlapping oligonucleotides. The upper band observed in the 300-bp fragment disappeared as the fragments became smaller while the lower band remained, regardless of probe size. EMSA analysis showed complex formation with a 33-bp oligonucleotide probe representing the sequence between Ϫ165 and Ϫ132 ( Figure 2C ). Within this oligonucleotide exists an NF1 transcription factor consensus binding sequence.
Evidence that the NF1 site was specifically responsible for the protein binding was sought by performing EMSA analysis with 3 25-bp overlapping fragments containing either the complete or a partial NF1 binding sequence ( Figure 3A) . Only the fragment containing the complete NF-1 consensus sequence showed binding activity in both lung and brain. Neither kidney ( Figure 3A ) nor liver (data not shown) displayed specific binding of a protein to the probe indicating that the DNA-protein interaction was not a common occurrence among the various organs. To determine whether the protein binding region represented the NF1 consensus sequence, competition binding studies and mutational analysis were performed. The NF1 consensus sequence was mutated at positions critical for the recognition by NF1 ( Figure 3B ) and the mutated oligonucleotide analyzed by EMSA. No complexes were formed between the mutated NF1 sequence in either the lung or brain extracts. Binding could also be eliminated by competition with the complete NF1 sequence. Competition for binding with fragments a or c (sequence shown in Figure 3A ) that contained partial NF1 consensus sequences had no effect on the binding activity of fragment b indicating that the intact sequence was necessary for protein binding.
Functional Role of the NF1 Consensus Sequence
To determine whether the promoter fragment studied can support transcriptional activity in cells that express tPA endogenously, adenoviral constructs containing the tPA promoter sequence Ϫ609 to ϩ37 placed upstream from the coding sequence of GFP were added to cultures of HeLa cells, dermal microvascular cells, umbilical vein endothelial cells, and GFP expression evaluated (Figure 4) . Photomicrographic analysis shows that GFP is expressed at detectable levels in each of these cells within 48 hours after infection. Infection of B109 cells, a neuroendocrine cell line, showed no GFP expression in the presence of the tPA promoter but were positive when the CMV promoter was substituted (data not shown). Mock infection controls were blank. A more detailed analysis of tPA promoter-driven GFP expression was performed by FACS using the 600 bp promoter-GFP (Ϫ609 to ϩ37) construct, a shorter promoter sequence containing sequence Ϫ289 to ϩ37, and each of these with a mutation residing in the NF-1 site ( Figure 5) . In endothelial cells, the lowest level of GFP expression was observed with the 600-bp fragment. A significant increase in expression (2.8-fold) occurred when the NF1 site was mutated (as in Figure 3C ). Reduction in the length of the promoter to include the sequence from Ϫ287 to ϩ37 also resulted in an increase in GFP expression even though the NF1 site was intact. A further increase in GFP expression was observed when the NF1 site was altered in this shortened fragment substantiating the results with the 600 bp promoter. When these studies were repeated with smooth muscle cells, no GFP expression was observed with any of the constructs despite the fact that cells infected with virus containing the CMV in place of the tPA promoter expressed as efficiently as the endothelial cells. In HeLa cells, GFP expression followed the same pattern as with the endothelial cells, with an increase when the NF1 site was mutated and when the fragment was shortened to 300 bp.
Discussion
In this study, we examined the possibility that regulatory elements within the tPA promoter region are involved with the control of limited endothelial cell tPA expression. Using a fragment consisting of the promoter sequence spanning Ϫ609 to ϩ37, we performed EMSA analysis with nuclear fractions derived from brain and lung. The rationale for choosing these 2 organs is the presence of tPA producing endothelium, a condition that is absent from other organs analyzed. Fifteen-day-old animals were used because of the continued development of the lung and brain vasculature with the attending proliferation of arterial endothelial cells. Such development would require continued transcriptional activity of the tPA gene. Within this fragment there appeared a protein binding activity that resided in an NF1 consensus sequence within 200-bp of the transcriptional start site. Commensurate with its protein binding activity is the repression of GFP expression as demonstrated by an increase in GFP expression in both endothelial and HeLa cells when the NF1 was altered. Cell specificity was suggested because smooth muscle cells and neuroendocrine cells infected with the virus containing the wild-type promoters had no detectable GFP expression. These findings are consistent with our hypothesis that the tPA promoter is responsible for regulating tPA expression in a cell type-dependent manner. This is also supported by the absence of specific binding in kidney and liver, neither of which have detectable levels of endothelial cell tPA expression. 10 Parallel results between endothelial cells and HeLa cells also were reported in other studies using plasmids containing promoter-reporter gene constructs containing 410 bp of the proximal promoter region. 24 These constructs were sufficient to generate detectable levels of basal reporter activity in transfected endothelial cells and and overlapping fragments that contain a partial NF1 sequence Ϫ173 to Ϫ149 (fragment 1) and Ϫ152 to Ϫ128 were generated and protein binding activity tested by EMSA as described. Lane 1, no extract; lane 2, 2.3 g nuclear extract; lane 3, unlabeled specific competitor (100-fold excess); lane 4, nonspecific competitor (100-fold). B, Competition binding experiments between the three oligonucleotides shown in 3A and sequence Ϫ165 to Ϫ132 were performed to assess the role of flanking regions of the NF1. Gel shift assay reaction mixtures contained biotinlabeled oligonucleotide Ϫ165 to Ϫ132 and 100-fold excess of a, b, or c, or an NF1 consensus sequence 5Ј-TTTTGGATTGAAGCCAATATGATAA-3Ј. C, The specificity of the NF1 site in protein binding was evaluated by site directed mutagenesis. Base substitutions are shown in italics and the NF1 sequence is underlined. EMSA analysis was then performed as described.
HeLa cells and in both cases were responsive to phorbol esters. HeLa cells produce endogenous tPA in culture and studies of the regulation of tPA antigen expression show a pattern consistent with endothelial cell regulation. 24 -26 An unexpected result in these studies was the increase in repressor activity when the portion of the promoter containing sequence Ϫ609 to Ϫ288 was removed from the construct. With this shorter construct, GFP expression increased considerably whether the NF1 was mutated. This region has no known regulatory elements and binding assays of fragment 2 and 3 ( Figure 2 ) that contain all or part of this region show no bands that are specific to both lung and brain. These data suggest that the presence of this promoter fragment enhances the repressor activity of the NF1 through secondary effects, eg, by altering the structure of the DNA to allow for increased function at the NF1 site or that a factor exists within the cultured cells that is not present/detectable in tissues by EMSA.
The NF1 family of nuclear regulatory factors can both activate and repress gene transcription. 27, 28 In addition, NF1 can repress a promoter in 1 type of cell whereas activating the same promoter in another. 29 Transcriptional repressors regulate gene expression by at least 2 distinct mechanisms. Nuclear proteins may compete with positive transcriptional activators for common DNA-binding sites, preventing binding of such factors, or destabilizing bound factors. 30 They may also contain intrinsic repressor activity and the capacity to downregulate transcription through internal domains. It is not clear in the case of the tPA promoter whether the NF1 binding protein is acting passively or actively. However, the proximity of the NF1 site to a CRE (Figure 1 ) creates the opportunity for interaction between the 2 factors, an event that has been observed in other promoters. [31] [32] [33] In addition to the NF1 site, other regulatory elements within the first 200 bp of the proximal promoter region have been associated with regulation of constitutive t-PA expression as well as induction of expression in response to various agonists. 15, 20, 21, 24, 27, 34, 35 In HeLa cells, a cAMP response-like element and an SP-1 site act cooperatively to mediate phorbol-ester-mediated induction of tPA gene expression, and in endothelial cells cyclic Endothelial cells were infected with adenoviral constructs containing the tPA promoter encompassing bases Ϫ609 to ϩ37 (panel 1), Ϫ289 to ϩ37 (panel 2), Ϫ609 to ϩ37 with base substitutions in the NF1 site (panel 3), and Ϫ289 to ϩ37 with the same mutations in the NF1 site (panel 4). Base substitutions are the same as those shown in Figure 3C and eliminate protein binding to the site. All cells were infected at 50 pfu/cell with either viral constructs containing the tPA promoters or CMV promoter. The construct used in panel 1 (Ϫ609 to ϩ37) correlates to the conditions used in Figure 4 . B, Comparison of GFP expression in endothelial cells, smooth muscle cells, and HeLa cells infected with the various wild-type and mutant promoter constructs described. Data are presented as a percent of the number of cells infected with CMV-GFP viral construct and which are expressing GFP. Endo indicates endothelial cells; smc, smooth muscle cells.
strain induction was shown to be dependent on the CRE and an AP-2 site. 26, 36 In summary, this study identifies a binding sequence in the tPA promoter that binds to an as yet unidentified protein found in the nuclear extract of lung and brain. This protein acts as a repressor of tPA expression in endothelial cells and other cells that produce tPA in vitro. In addition, promoter activity is absent in smooth muscle cells that are incapable of producing tPA in vivo.
